


Depression continues to be Canada's fastestrising diagnosis. From 1994 to 2004, visits to office-based physicians for depression have almost doubled. The majority of visits were made by Canadians aged 40 to 64 (57% of visits), followed by those aged 20 to 39 (29% of visits).

Prescriptions of all classes of antidepressants have almost doubled since 1999, climbing to 22.5

million in 2004, with a retail value of \$1.1 billion. The most commonly prescribed antidepressants are selective serotonin re-uptake inhibitors (SSRIs), accounting for 75% of all prescriptions dispensed last year.

A provincial comparison of the per capita consumption of SSRIs in Canada shows that Manitoba leads the country with 25.2 pills per



capita dispensed in 2004, followed by the Maritimes and Alberta at 24.3 and 23.8 pills per capita, respectively. At 14.9 pills per capita, Saskatchewan is well below the national average of 21.1 pills per person. Also at or below the national average are Ontario (21.1 pills per capita) and Quebec (19.4 pills per capita). CPM

Source: CompuServe. Copyright® 2005 IMS HEALTH Canada. All Rights Reserved.

THERAPEUTIC TRENDS is made available by IMS Health Canada, providing vital information solutions to the Canadian health-care community since 1970. IMS Health Canada is a subsidiary of IMS Health Inc., the world's leading provider of information and consulting solutions to the pharmaceutical and health-care industries in over 100 countries. IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovation; and consulting services that improve the delivery of health care worldwide. For more information, please contact an IMS representative.

Montreal, QC (514) 428-6000 Mississauga, ON (905) 816-5000

## **Promotion**

## Patrick Gushue President of Pangaea's new division



Patrick Gushue

Joseph Knott, President of Pangaea Holdings Inc., is pleased to announce the creation of a new division for the Pangaea group of companies. The new division, Pangaea Development & Training, will focus on improving marketing and sale force effectiveness through directed learning. In addition to facilitating the Canadian Pharmaceutical Marketing Program at Humber Institute of Technology and Advanced Learning and one-to-one mentoring, the division will be assisting companies with the development of internal talent management programs for marketing and sales professionals.

Mr. Knott is also pleased to announce that Patrick Gushue has been appointed President of this new division. Patrick began his career as a pharmaceutical sales representative and rose quickly through management with various companies, holding positions such as Director, Marketing and Sales, Vice-President, Marketing, and Vice-President, Business Development. Patrick holds two Bachelor of Arts degrees, a degree in Education and a Masters degree in Business Administration. His MBA research focused on Pharmaceutical Product Manager Training and led to the design and implementation of competency-based development programs for Associate Product Managers and Product Managers.

